Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 81
-0.03%-2.32%+22.53%+68.67% 49.03B
-1.14%+13.15%+60.80%+127.29% 42.33B
+0.27%-0.37%-1.22%+15.93% 12.43B
+0.43%-0.69%+19.53%+69.15% 11.68B
-0.67%+0.39%+31.23%+141.20% 9.12B
+3.81%+7.21%+22.98%+37.90% 7.15B
+1.62%+1.47%+41.67%-12.77% 7.09B
-1.22%+0.78%+11.47%+171.70% 6.76B
+0.03%+8.29%-24.59%+28.71% 5.95B
Average +0.36%+2.47%+20.49%+71.98% 16.84B
Weighted average by Cap. -0.08%+3.66%+30.14%+82.88%
Logo PixarBio Corporation
PixarBio Corporation is a specialty pharmaceutical company that is focused on the pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain. The Company’s lead product platform, NeuroRelease, is a novel biodegradable microparticle delivery system for the delivery of non-opiate prescription paid drugs. NeuroRelease offers sustained therapeutic pre-clinical release over time of a non-opiate drug for post-operative, acute, and chronic pain in pre-clinical models involving rodents and pigs. NeuroRelease treats multiple conditions, including pain, Parkinson’s disease, epilepsy, and spinal cord injury. NeuroRelease is biodegradable, and it is non-toxic so it can be re-injected to extend treatment timelines. Its Injectable NeuroScaffold is a platform to advance from acute neuro-protective spinal cord injury treatment to a regeneration treatment for chronic spinal cord injury.
Employees
30
  1. Stock Market
  2. Stocks
  3. PXRB Stock